A phase I clinical trial of immunotherapy with interferon-γ gene-modified autologous melanoma cells: Monitoring the humoral immune response

Cancer

Volumn 80, Issue 3, 1997, Pages 401-412

  Abdel Wahab, Zeinab ^a,c   Weltz, Christina ^a   Hester, Dina ^a   Pickett, Nancy ^a   Vervaert, Carol ^a   Barber, Jack R ^b   Jolly, Douglas ^b   Seigler, Hilliard F ^a  

^a DUKE UNIVERSITY   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Gene therapy; Interferon ; Malignant melanoma; Retrovirus; Specific active immunotherapy; Transduction

Indexed keywords

RECOMBINANT GAMMA INTERFERON;

ANTIGEN RECOGNITION; ARTICLE; CELL VIABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOTHERAPY; MELANOMA CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

CANCER VACCINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY, ACTIVE; INTERFERON TYPE II; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MELANOMA; MIDDLE AGED; RADIOIMMUNOASSAY; RADIOIMMUNOPRECIPITATION ASSAY; REMISSION INDUCTION;

EID: 0030820018     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970801)80:3<401::AID-CNCR8>3.0.CO;2-U     Document Type: Article

References (40)

1. Herlyn M, Koprowski H. Melanoma antigens: immunological and biological characterization and clinical significance. Ann Rev Immunol 1988;6:283-308.
2. Herlyn M, Rodeck U, Koprowski H. Shedding of tumor-associated antigens in vitro and in vivo. Adv Cancer Res 1987;49:189-221.
3. Golumbek P, Lazenby A, Levitsky H, Jaffee L, Karasuyama H, Baker M, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-6.
4. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990;172:1217-24.
5. Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E. Regression of bladder tumors in mice treated with interleukin-2 gene-modified tumor cells. J Exp Med 1993;177:1127-34.
6. Abdel-Wahab Z, Li W-P, Osanto S, Darrow TL, Hessling J, Vervaert C, et al. Transduction of human melanoma cells with interleukin-2 gene reduces tumorigenicity and enhances host anti-tumor immunity: a nude mouse model. Cell Immunol 1994;159:26-39.
7. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector mediated gamma interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990;50:7820-5.
8. Ogasawara M, Rosenberg S. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma IFN genes. Cancer Res 1993;53:3561-8
9. Dar M, Abdel-Wahab Z, Vervaert C, Darrow T, Barber J, Seigler HF. Transduction with the murine interferon gamma gene leads to long-term immunological memory. Ann Surg Oncol 1996;3:247-54.
10. Porgador A, Tzehoval E, Katz A, Vadai E, Revel M, Feldman M, et al. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 1992;52:3679-86.
11. Hock H, Dorsch M, Diamantstein T, Blankenstein T. Interleukin-7 induces CD4+ T cell-dependent tumor rejection. J Exp Med 1991;174:1291-8.
12. Blankenstein T, Qin Z, Uberla K, Muller W, Rosen H, Volk HD, et al. Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J Exp Med 1991;173:1047-52.
13. Colombo MP, Ferrari G, Stoppacciaro A, Parenza M, Rodolfo M, Mavilio F, et al. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 1991;173:889-97.
14. Baron S, Coppenhaver DH, Dianzani F, Fleischmann WR, Hughes TK, Klimpel GR, et al. Introduction to the interferon system. In: Baron S, Coppenhaver DH, Dianzani F, editors. Interferon, principle and medical applications. Galveston, TX: University of Texas, 1992:1-15.
15. Morikawa K, Kubagawa H, Suzuki T, Cooper MD. Recombinant interferon alpha, beta, and gamma enhance the proliferative response of human B cells. J Immunol 1987;139:761-6.
16. Nakagawa T, Hirano T, Nakagawa N, Yoshizaki K, Kishimoto T. Effect of recombinant IL-2 and IFN-gamma on proliferation and differentiation of human B cells. J Immunol 1985;134:959-66.
17. Abdel-Wahab Z, Osanto S, Darrow TL, Barber J, Vervaert C, Gangavalli R, et al. Transduction of human melanoma cells with the gamma Interferon gene enhances cellular immunity. Cancer Gene Ther 1994;1:171-9.
18. Watanabe Y, Kuribayashi K, Miyatake S, Nishihara K, Nakayama E-I, Taniyama T, et al. Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA 1989;86:9456-60.
19. Seigler HF, Darrow TL, Abdel-Wahab ZA, Gangavalli R, Barber J. Clinical protocol: a phase I trial of human gamma interferon transduced autologous tumor cells in patients with disseminated malignant melanoma. Hum Gene Ther 1994;5:761-77.
20. Howard B, Burrascano M, McCallister T, Chong K, Gangavalli R, Severinsson L, et al. Retroviral mediated gene transfer of the human gamma interferon gene: a therapy for cancer. Ann N Y Acad Sci 1994;716:167-87.
21. Armentano D, Yu SF, Kantoff PS, von Ruden T, Anderson WF. Effect of internal viral sequences on the utility of retroviral vectors. J Virol 1987;61:1647-50.
22. Brennan GL, Kronenberg LH. Automated bioassay of interferons in microtest plate. Biotechniques 1983;1:78-82.
23. Carrel S, Accolla RS, Carmagnola AL, Mach J-P. Common human melanoma associated antigen(s) detected by monoclonal antibodies. Cancer Res 1980;40:2523-8.
24. Abdel-Wahab Z, Li W-P, Darrow T, Nudelman ED, Towell A, Seigler HF. Cell surface reactive human monoclonal anti-body directed to human melanoma-associated gangliosides. Melanoma Res 1993;3:415-23.
25. Abdel-Wahab Z, Gillanders W, Darrow T, Seigler HF. Generation of human IgG, IgA, and IgM anti-melanoma monoclonal antibodies utilizing lymphocytes of an actively immunized melanoma patient. Hum Antibodies Hybridomas 1992;3:32-9.
26. Goding JW Analysis of antigens recognized by monoclonal antibodies. In: Monoclonal antibodies: principles and practice. London, Academic Press Inc., 1983: 141-3.
27. Abdel-Wahab Z, Dar M, Hester D, Verveart C, Barber J, Darrow T, et al. Effect of irradiation on cytokine production, MHC expression and the vaccine potential of interleukin-2 and IFN-γ gene modified melanoma cells. Cell Immunol 1996;171:246-54.
28. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulated potent, specific, and long-lasting anti-tumor immunity. Ptoc Natl Acad Sci USA 1993; 90:3539-43.
29. Pfeiffer C, Murray J, Madri J, Bottomly K. Selective activation of Th1- and Th2-like cells in vivo: response to human collagen IV. Immunol Rev 1991;123:65-84.
30. Nickerson P, Steurer W, Steiger J, Zheng X, Steele A, Strom T. Cytokines and the Th1/Th2 paradigm in transplantation. Curr Opin Immunol 1994;6:757-64.
31. Pardoll DM. Cancer vaccines. Immunol Today 1993;14:310-6.
32. Ostrand-Rosenberg S, Roby C, Clements V. Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule. J Immunol 1991;147:2419-22.
33. Ostrand-Rosenberg S. Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr Opin Immunol 1994;6:722-7.
34. Morton DL, Foshag LJ, Hoon D, Nizzie JA, Wanek LA, Chang C, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992;216:463-82.
35. Mitchell M, Harel W, Kempf R, Hu E, Kan-Mitchell J, Boswell WD, et al. Active-specific immunotherapy for melanoma. J Clin Oncol 1990;8:856-69.
36. Crowley NJ, Slingluff CL, Darrow TL, Seigler HF. Generation of human autologous melanoma-specific cytotoxic T cells using HLA-A2 matched allogeneic melanomas. Cancer Res 1990;50:492-8.
37. Mattes JM, Thomson TM, Old LJ, Lloyd KO. A pigmentation-associated differentiation antigen of human melanoma defined by a precipitating antibody in human serum. Int J Cancer 1983;32:717-21.
38. Vijayasaradhi S, Bouchard B, Houghton AN. The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med 1990;171:1375-80.
39. Hearing VJ, Ekel TM, Montague PM. Mammalian tyrosinase: isomeric forms of the enzyme. Int J Biochem 1981;13:89-103.
40. Porgador A, Bannerji R, Watanabe Y, Feldman M, Gilboa E, Eisenbach L. Antimetastatic vaccination of tumor-bearing mice with two types of γIFN gene-inserted tumor cells. J Immunol 1993;4:1458-70.